Ludvigsen, Maja http://orcid.org/0000-0001-5089-3271
Campbell, Amanda Jessica http://orcid.org/0009-0003-3582-3728
Enemark, Marie Beck
Hybel, Trine Engelbrecht
Karjalainen-Lindsberg, Marja-Liisa
Beiske, Klaus
Bjerre, Mette
Pedersen, Lars Møller
Holte, Harald
Leppä, Sirpa http://orcid.org/0000-0002-8265-511X
Jørgensen, Judit Meszaros
Honoré, Bent http://orcid.org/0000-0002-3459-7429
Funding for this research was provided by:
Karen Elise Jensens Fond (NA)
Institut for Klinisk Medicin, Aarhus Universitet (NA)
A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal (NA)
Article History
Received: 28 April 2023
Revised: 2 October 2023
Accepted: 11 October 2023
First Online: 26 October 2023
Competing interests
: BH holds shares from Novo Nordisk A/S and Genmab A/S. Novo Nordisk A/S and Genmab A/S had no influence on the study design, analyses, and reporting of the results. HH: Novartis: Advisory Board; Genmab: Safety Committee; Gilead: Consultancy; Roche: Advisory Board, Consultancy; Takeda: Advisory Board; Incyte: Advisory Board Committee; Nordic Nanovector: Safety Committee. SL: <i>Incyte*:</i> Consultancy, Honoraria; <i>Roche*:</i> Consultancy, Honoraria, Research Funding; <i>Genmab</i>*: Research Funding, <i>Orion*:</i> Consultancy, <i>Novartis*:</i> Consultancy, Research Funding, Honoraria; <i>Bayer*:</i> Research Funding; <i>Celgene*:</i> Consultancy, Research Funding. <i>Gilead*:</i> Consultancy. *Not related to this study. JMJ: <i>Incyte*:</i> Consultancy, <i>Roche*:</i> Consultancy; <i>Orion*:</i>Consultancy,<i>Novartis*:</i> Consultancy, C<i>elgene*:</i> Consultancy, Research Funding. <i>Gilead*:</i> Consultancy. <i>SOBI*:</i> Consultancy. <i>Abbvie*:</i> Consultancy *Not related to this study. All other authors declare no conflict of interest and all authors declare no competing financial interest in relation to the work described.